Abstract
Patients with programmed death-ligand 1 positive (PD-L1+), locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) have a poor prognosis and treatment options are limited. Sitravatinib, a selective tyrosine kinase inhibitor, reduces the number of myeloid-derived suppressor cells and regulatory T cells, promotes the expansion and migration of antitumor cytotoxic T cells, and increases the ratio of M1/M2-polarized macrophages. Tislelizumab, an anti-programmed cell death protein 1 (PD-1) antibody engineered to minimize binding to FcγR on macrophages, has shown clinical activity in patients with advanced solid tumors, including NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have